相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
Tanguy Y. Seiwert et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation
Yok-Lam Kwong
ANNALS OF HEMATOLOGY (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
14P * KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
L. Buisseret et al.
ANNALS OF ONCOLOGY (2015)
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
W. E. E. Eberhardt et al.
ANNALS OF ONCOLOGY (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
Evan Ni Alley et al.
CANCER RESEARCH (2015)
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
Caroline Gaudy et al.
DIABETES CARE (2015)
Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study
C. Hsu et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028
B. H. O'Neil et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
P. A. Ott et al.
EUROPEAN JOURNAL OF CANCER (2015)
Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
Y. J. Bang et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Acute skin reaction suggestive of pembrolizumab-induced radiosensitization
Vincent Sibaud et al.
MELANOMA RESEARCH (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The tumour microenvironment in B cell lymphomas
David W. Scott et al.
NATURE REVIEWS CANCER (2014)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria
Joshua M. Horne-Debets et al.
CELL REPORTS (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Christian Steidl et al.
NATURE (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
T Shin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
分享论文
